- Three studies are designed to help further unravel the potential of the field of cancer metabolism research;
- AnovaOS™ will be used to support site activation, patient identification and enrolment through just-in-time approach;
- AnovaOS™ will be used to support the delivery of three studies, for metastatic pancreatic cancer, metastatic colorectal cancer, and for PIK3CA mutated advanced solid tumors.
Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with an in-stealth US biopharmaceutical company to accelerate the development of metabolic treatments for patients with metastatic pancreatic cancer, metastatic colorectal cancer, and PIK3CA mutated advanced solid tumors.
Metabolomics, representing the whole molecular phenotype, is the study of substrates and products of the metabolism – a powerful approach because it directly reflects the underlying biomedical activity and state of a patients cells/tissues. Work in the last decade has taken cancer metabolism to become a key component of cellular transformation. These studies bring a deep mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment, and will help enable the matching of specific diets with tumor genotypes and treatment regimens with the aim of improving the outcomes of cancer therapy.
The three clinical trials are being made available to all cancer research centers across the U.S. for patients with for patients with metastatic pancreatic cancer, metastatic colorectal cancer, and PIK3CA mutated advanced solid tumors, using a just-in-time activation and enrolment mechanism aimed at delivering treatment to eligible patients in as little as five days.
“We are excited about the opportunity of accelerating the delivery of these three studies. Using diet to change the systemic and tumor specific metabolic context in which cancer treatments act has the potential to transform the efficacy of conventional cancer treatments and Anova is delighted to open these studies to cancer centers across the U.S.,’ said Martin Walsh, President at Anova. ‘AnovaOS™ is designed to allow patients to access the right treatment wherever they choose to receive care.’
Research sites and physicians interested in participating in any of these studies should sign up by registering their profile at www.anovaevidence.com. To find out more contact Wubet Redda, Clinical Trial Project Lead at wubet@anovaevidence.com
